PD-1阻害剤の世界市場:企業別、地域別、種類別、用途別、市場予測(~2024)

GlobalInfoResearchが発行した調査報告書(GIR9074470)
◆英語タイトル:Global PD-1 Inhibitor Market 2019 by Company, Regions, Type and Application, Forecast to 2024
◆商品コード:GIR9074470
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2019年6月(※2024年版があります。お問い合わせください。)
◆ページ数:122
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医薬品・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは、PD-1阻害剤の世界市場について調べ、まとめました。種類別セグメントは、ペンブロリズマブ、ニボルマブ、アテゾリズマブ、デュルバルマブ、アベルマブ、その他等、用途別セグメントは、等に区分しました。PD-1阻害剤の世界市場概観、企業動向、企業別PD-1阻害剤シェア、市場規模推移、市場規模予測(2019年-2024年)、主要地域分析(北米、ヨーロッパ、アジア等)、主要国分析(日本、中国、アメリカ等)データなどの情報が含まれています。
・PD-1阻害剤の市場概観
・PD-1阻害剤の企業概要(事業概要、製品種類、販売量、価格、売上、市場シェア等)
・PD-1阻害剤の企業別販売動向、市場シェア、市場集中度、競争動向
・PD-1阻害剤の世界市場規模
・PD-1阻害剤の北米市場分析(アメリカ、カナダ、メキシコ等)
・PD-1阻害剤のアメリカ市場規模推移
・PD-1阻害剤のカナダ市場規模推移
・PD-1阻害剤のメキシコ市場規模推移
・PD-1阻害剤のヨーロッパ市場分析(ドイツ、イギリス、ロシア、フランス、イタリア等)
・PD-1阻害剤のドイツ市場規模推移
・PD-1阻害剤のイギリス市場規模推移
・PD-1阻害剤のロシア市場規模推移
・PD-1阻害剤のアジア太平洋市場分析(日本、中国、韓国、インド、東南アジア等)
・PD-1阻害剤の日本市場規模推移
・PD-1阻害剤の中国市場規模推移
・PD-1阻害剤の韓国市場規模推移
・PD-1阻害剤のインド市場規模推移
・PD-1阻害剤の東南アジア市場規模推移
・PD-1阻害剤の南米市場分析(ブラジル、アルゼンチン等)
・PD-1阻害剤の中東・アフリカ市場分析(サウジアラビア、UAE、南アフリカ等)
・PD-1阻害剤の種類別分析/販売量、売上、市場シェア(ペンブロリズマブ、ニボルマブ、アテゾリズマブ、デュルバルマブ、アベルマブ、その他)
・PD-1阻害剤の用途別分析/市場規模()
・PD-1阻害剤の市場予測2019年-2024年(地域別予測、種類別予測、用途別予測)
・PD-1阻害剤の販売チャネル・代理店・貿易業者・ディーラー分析
【レポートの概要】

Scope of the Report:
The global PD-1 Inhibitor market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of PD-1 Inhibitor.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the PD-1 Inhibitor market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the PD-1 Inhibitor market by product type and applications/end industries.

Market Segment by Companies, this report covers
Merck
Novartis
Onxeo
Sumitomo Dainippon Pharma
Taiwan Liposome Company
Tiziana Life Sciences
Genentech (Roche)
AstraZeneca
Pfizer

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
Other

Market Segment by Applications, can be divided into
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Urothelial Carcinoma
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Other

【レポートの目次】

Table of Contents

1 PD-1 Inhibitor Market Overview
1.1 Product Overview and Scope of PD-1 Inhibitor
1.2 Classification of PD-1 Inhibitor by Types
1.2.1 Global PD-1 Inhibitor Revenue Comparison by Types (2019-2024)
1.2.2 Global PD-1 Inhibitor Revenue Market Share by Types in 2018
1.2.3 Pembrolizumab
1.2.4 Nivolumab
1.2.5 Atezolizumab
1.2.6 Durvalumab
1.2.7 Avelumab
1.2.8 Other
1.3 Global PD-1 Inhibitor Market by Application
1.3.1 Global PD-1 Inhibitor Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Melanoma
1.3.3 Non-small Cell Lung Cancer (NSCLC)
1.3.4 Urothelial Carcinoma
1.3.5 Classical Hodgkin Lymphoma
1.3.6 Renal Cell Carcinoma
1.3.7 Other
1.4 Global PD-1 Inhibitor Market by Regions
1.4.1 Global PD-1 Inhibitor Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) PD-1 Inhibitor Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) PD-1 Inhibitor Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) PD-1 Inhibitor Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) PD-1 Inhibitor Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) PD-1 Inhibitor Status and Prospect (2014-2024)
1.5 Global Market Size of PD-1 Inhibitor (2014-2024)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Business Overview
2.1.2 PD-1 Inhibitor Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Merck PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.2 Novartis
2.2.1 Business Overview
2.2.2 PD-1 Inhibitor Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.3 Onxeo
2.3.1 Business Overview
2.3.2 PD-1 Inhibitor Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Onxeo PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.4 Sumitomo Dainippon Pharma
2.4.1 Business Overview
2.4.2 PD-1 Inhibitor Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.5 Taiwan Liposome Company
2.5.1 Business Overview
2.5.2 PD-1 Inhibitor Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Taiwan Liposome Company PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.6 Tiziana Life Sciences
2.6.1 Business Overview
2.6.2 PD-1 Inhibitor Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Tiziana Life Sciences PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.7 Genentech (Roche)
2.7.1 Business Overview
2.7.2 PD-1 Inhibitor Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Genentech (Roche) PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.8 AstraZeneca
2.8.1 Business Overview
2.8.2 PD-1 Inhibitor Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 AstraZeneca PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
2.9 Pfizer
2.9.1 Business Overview
2.9.2 PD-1 Inhibitor Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Pfizer PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2018)
3 Global PD-1 Inhibitor Market Competition, by Players
3.1 Global PD-1 Inhibitor Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 PD-1 Inhibitor Players Market Share
3.2.2 Top 10 PD-1 Inhibitor Players Market Share
3.3 Market Competition Trend
4 Global PD-1 Inhibitor Market Size by Regions
4.1 Global PD-1 Inhibitor Revenue and Market Share by Regions
4.2 North America PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
4.3 Europe PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
4.5 South America PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
5 North America PD-1 Inhibitor Revenue by Countries
5.1 North America PD-1 Inhibitor Revenue by Countries (2014-2019)
5.2 USA PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
5.3 Canada PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
5.4 Mexico PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
6 Europe PD-1 Inhibitor Revenue by Countries
6.1 Europe PD-1 Inhibitor Revenue by Countries (2014-2019)
6.2 Germany PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
6.3 UK PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
6.4 France PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
6.5 Russia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
6.6 Italy PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
7 Asia-Pacific PD-1 Inhibitor Revenue by Countries
7.1 Asia-Pacific PD-1 Inhibitor Revenue by Countries (2014-2019)
7.2 China PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
7.3 Japan PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
7.4 Korea PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
7.5 India PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
8 South America PD-1 Inhibitor Revenue by Countries
8.1 South America PD-1 Inhibitor Revenue by Countries (2014-2019)
8.2 Brazil PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
8.3 Argentina PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
8.4 Colombia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue PD-1 Inhibitor by Countries
9.1 Middle East and Africa PD-1 Inhibitor Revenue by Countries (2014-2019)
9.2 Saudi Arabia PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
9.3 UAE PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
9.4 Egypt PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
9.5 Nigeria PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
9.6 South Africa PD-1 Inhibitor Revenue and Growth Rate (2014-2019)
10 Global PD-1 Inhibitor Market Segment by Type
10.1 Global PD-1 Inhibitor Revenue and Market Share by Type (2014-2019)
10.2 Global PD-1 Inhibitor Market Forecast by Type (2019-2024)
10.3 Pembrolizumab Revenue Growth Rate (2014-2024)
10.4 Nivolumab Revenue Growth Rate (2014-2024)
10.5 Atezolizumab Revenue Growth Rate (2014-2024)
10.6 Durvalumab Revenue Growth Rate (2014-2024)
10.7 Avelumab Revenue Growth Rate (2014-2024)
10.8 Other Revenue Growth Rate (2014-2024)
11 Global PD-1 Inhibitor Market Segment by Application
11.1 Global PD-1 Inhibitor Revenue Market Share by Application (2014-2019)
11.2 PD-1 Inhibitor Market Forecast by Application (2019-2024)
11.3 Melanoma Revenue Growth (2014-2019)
11.4 Non-small Cell Lung Cancer (NSCLC) Revenue Growth (2014-2019)
11.5 Urothelial Carcinoma Revenue Growth (2014-2019)
11.6 Classical Hodgkin Lymphoma Revenue Growth (2014-2019)
11.7 Renal Cell Carcinoma Revenue Growth (2014-2019)
11.8 Other Revenue Growth (2014-2019)
12 Global PD-1 Inhibitor Market Size Forecast (2019-2024)
12.1 Global PD-1 Inhibitor Market Size Forecast (2019-2024)
12.2 Global PD-1 Inhibitor Market Forecast by Regions (2019-2024)
12.3 North America PD-1 Inhibitor Revenue Market Forecast (2019-2024)
12.4 Europe PD-1 Inhibitor Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific PD-1 Inhibitor Revenue Market Forecast (2019-2024)
12.6 South America PD-1 Inhibitor Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa PD-1 Inhibitor Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ PD-1阻害剤の世界市場:企業別、地域別、種類別、用途別、市場予測(~2024)(Global PD-1 Inhibitor Market 2019 by Company, Regions, Type and Application, Forecast to 2024)]についてメールでお問い合わせはこちらでお願いします。